ABSTRACT
Assessment of the benefit/risk ratio for drugs and chemicals from in vitro data is currently receiving unprecedented attention. Increasingly tough legislation and the consequent development cost increases associated with social and political demands to reduce in vivo animal experiments constitute the main incentives for food and drugs, chemical, and cosmetics industries to actively search for suitable in vitro procedures to evaluate the activity and toxicity of their molecules.1
